ferroquine

Ferroquine is a synthetic organometallic antimalarial drug structurally related to chloroquine but distinguished by the incorporation of a ferrocene moiety. It was developed as part of efforts to overcome resistance to traditional aminoquinoline antimalarials. Ferroquine acts primarily as a hemozoin inhibitor, disrupting the detoxification pathway of heme in Plasmodium parasites. It has demonstrated potent activity against both chloroquine-susceptible and chloroquine-resistant strains of Plasmodium falciparum and P. vivax[4][5]. The drug has been evaluated in multiple phase II clinical trials for uncomplicated malaria but development for this indication was discontinued after phase II[4][5]. Ferroquine is also being investigated for potential repositioning as an anticancer agent[3].

Other names

ferrochloroquineferrocene-quinoline conjugate